P MMUT 101
Alternative Names: P-MMUT-101Latest Information Update: 28 Jan 2024
At a glance
- Originator Poseida Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference; Methylmalonyl CoA mutase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Methylmalonic acidaemia
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for research development in Methylmalonic-acidaemia in USA (Parenteral)
- 18 Dec 2019 Early research in Methylmalonic acidaemia in USA (Parenteral) (Poseida Therapeutics pipeline, December 2019)
- 13 Feb 2019 Poseida Therapeutics receives patent allowance for a patent protecting its piggyBac® DNA Modification System in USA